Cannabis? CBD? That’s Old News, A New Sector Bull Run Has Begun


New York, NY -- April 16, 2020 -- InvestorsHub NewsWire -- via Traders News Source -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies’ issues their latest research “The Next Hot Sector”

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers.  It has completed a 40-patient Phase I trial and is preparing for Phase II trials.  The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Amarin Corporation plc (NASDAQ: AMRN) is focused on its lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries. VASCEPA® (icosapent ethyl), capsules, was originally approved in 2012 to reduce severely elevated levels of triglycerides. The drug’s approval was expanded in 2019 as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in certain adults with elevated triglyceride levels of 150 milligrams per deciliter or higher and other cardiovascular risk factors. On March 6th, the company reaffirmed its outlook for 2020 with revenues expected to range from $650 million to $700 million.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome and other central nervous system (CNS) diseases. recently, the company announced the publication of foundational data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS). The data showed that   ANAVEX®2-73, in an invitro study, impacts the central nervous system in a unique way. There are effective disease-modifying therapies (DMTs) approved for treatment of patients with relapsing remitting MS, however, none of these DMTs are cures and many have significant side effects.

Kiwa Bio-Tech Products Group Corporation (OTCQB: KWBT) is an agricultural company that develops, manufactures and markets bio-fertilizers for use in the multi-billion China agriculture and aquaculture markets and the developer of smart soil remediation technology for use in agriculture markets. Wade Li has recently been installed as the new CEO. Focusing on China’s nearly 35 billion USD new fertilizer market, as well as nearly trillion USD soil remediation market, Kiwa will rely on its existing business to expand fertilizer market share, to obtain soil remediation market share.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required –

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
The sponsored and non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our report(s), disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Northwest Biotherapeutics (QB) Charts.